You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Troglitazone
Troglitazone is a selective PPARγ receptor agonist (EC50 values are 780 and 555 nM at murine and human PPARγ receptors respectively). Displays no activity at PPARα or PPARδ receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.
Compound Libraries for Troglitazone
Technical Data for Troglitazone
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Troglitazone
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Troglitazone
The following data is based on the product molecular weight 441.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.26 mL||11.32 mL||22.65 mL|
|5 mM||0.45 mL||2.26 mL||4.53 mL|
|10 mM||0.23 mL||1.13 mL||2.26 mL|
|50 mM||0.05 mL||0.23 mL||0.45 mL|
References for Troglitazone
References are publications that support the biological activity of the product.
Lee and Olefsky (1995) Acute effects of troglitazone on in vivo Ins action in normal rats. Metabolism 44 1166 PMID: 7666790
Kodera et al (2000) Ligand type-specific interactions of peroxisome-proliferator-activated receptor γ with transcriptional coactivators. J.Biol.Chem. 275 33201 PMID: 10944516
Willson et al (2000) The PPARs: from orphan receptors to drug discovery. J.Med.Chem. 43 527 PMID: 10691680
Fujimura et al (1998) Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int.J.Oncol. 13 1263 PMID: 9824642
If you know of a relevant reference for Troglitazone, please let us know.
View Related Products by Product Action
Keywords: Troglitazone, Troglitazone supplier, Selective, PPARγ, PPARgamma, agonists, antidiabetic, agent, Peroxisome, Proliferator-activating, Receptors, Rezulin, Stem, Cell, Proliferation, 3114, Tocris Bioscience
3 Citations for Troglitazone
Citations are publications that use Tocris products. Selected citations for Troglitazone include:
Ross et al (2017) Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and sora. Cell Chem Biol 24 813 PMID: 28625738
Hegde et al (2015) Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo. J Immunol 194 5211 PMID: 25917103
Bisikirska et al (2016) Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression. Cancer Res 76 664 PMID: 26589882
Do you know of a great paper that uses Troglitazone from Tocris? Please let us know.
Reviews for Troglitazone
There are currently no reviews for this product. Be the first to review Troglitazone and earn rewards!
Have you used Troglitazone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.